WallStreetZenWallStreetZen

NASDAQ: ANTX
An2 Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ANTX stock forecasts and price targets.

Forecast return on equity

Is ANTX forecast to generate an efficient return?

Company
-37.03%
Industry
76.22%
Market
343.1%
ANTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ANTX forecast to generate an efficient return on assets?

Company
-33.26%
Industry
22.81%
ANTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ANTX earnings per share forecast

What is ANTX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.08
Avg 2 year Forecast
-$0.95
Avg 3 year Forecast
-$0.82

ANTX revenue forecast

What is ANTX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ANTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ANTX$1.07N/AN/A
PASG$9.18$34.50+275.69%Strong Buy
BRNS$0.72$4.00+454.79%Buy
NRXS$2.71$7.00+158.30%Buy
NRSN$1.20$14.00+1,066.67%Strong Buy
View Top Biotech Stocks

An2 Therapeutics Stock Forecast FAQ

What is ANTX's earnings growth forecast for 2025-2027?

(NASDAQ: ANTX) An2 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 74.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.59%.

An2 Therapeutics's earnings in 2025 is -$33,986,000.On average, 4 Wall Street analysts forecast ANTX's earnings for 2025 to be -$29,487,318, with the lowest ANTX earnings forecast at -$30,076,462, and the highest ANTX earnings forecast at -$28,484,404. On average, 4 Wall Street analysts forecast ANTX's earnings for 2026 to be -$26,133,310, with the lowest ANTX earnings forecast at -$25,779,824, and the highest ANTX earnings forecast at -$26,182,634.

In 2027, ANTX is forecast to generate -$22,360,052 in earnings, with the lowest earnings forecast at -$21,483,187 and the highest earnings forecast at -$23,017,700.

If you're new to stock investing, here's how to buy An2 Therapeutics stock.

What is ANTX's revenue growth forecast for 2025-2027?

(NASDAQ: ANTX) An2 Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 289.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.77%.

An2 Therapeutics's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast ANTX's revenue for 2025 to be $0, with the lowest ANTX revenue forecast at $0, and the highest ANTX revenue forecast at $0. On average, 4 Wall Street analysts forecast ANTX's revenue for 2026 to be $0, with the lowest ANTX revenue forecast at $0, and the highest ANTX revenue forecast at $0.

In 2027, ANTX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ANTX's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: ANTX) forecast ROA is -33.26%, which is lower than the forecast US Biotechnology industry average of 22.81%.

What is ANTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ANTX) An2 Therapeutics's current Earnings Per Share (EPS) is -$1.12. On average, analysts forecast that ANTX's EPS will be -$1.08 for 2025, with the lowest EPS forecast at -$1.10, and the highest EPS forecast at -$1.04. On average, analysts forecast that ANTX's EPS will be -$0.95 for 2026, with the lowest EPS forecast at -$0.94, and the highest EPS forecast at -$0.96. In 2027, ANTX's EPS is forecast to hit -$0.82 (min: -$0.78, max: -$0.84).

What is ANTX's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: ANTX) forecast ROE is -37.03%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.